ArriVent BioPharma, Inc. (AVBP) AI Stock Analysis

• Market Cap: $558.55M
• Dividend Yield: N/A
• Average Volume (3M): 236.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.13
• Revenue Growth: N/A
• EPS Growth: -15.71%
• Country: US
• Employees: 52
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -2.40
• Shares Outstanding: 34,016,197
• 10 Day Avg. Volume: 300,314
• 30 Day Avg. Volume: 236,986
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -10.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $39.75
• Price Target Upside: 142.08% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

ArriVent BioPharma's financial performance is constrained by lack of revenue and ongoing losses typical of a biotech in the R&D phase. Technical indicators suggest bearish trends, and valuation metrics are not favorable. However, the recent licensing agreement adds potential future value by expanding its oncology pipeline.

Positive Factors

Clinical Trials

The FURTHER trial demonstrated promising response rates for firmonertinib, with a confirmed objective response rate of 63.6% at the 240mg dose.

Market Opportunity

There is currently no FDA-approved agent for non-small cell lung cancer patients with EGFR PACC mutations, highlighting the potential market opportunity for firmonertinib.

Negative Factors

Financial Challenges

The company has less than two years of cash runway remaining, which may pose financial challenges.

Investor Sentiment

Short interest for the company's stock is at 19.5%, which may indicate a bearish sentiment among investors.

ArriVent BioPharma, Inc. Business Overview & Revenue Model

Company Description

ArriVent BioPharma, Inc. (AVBP) is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of cancer and other serious diseases. The company leverages its expertise in drug development and strategic partnerships to bring advanced therapeutic solutions to the global market.

How the Company Makes Money

ArriVent BioPharma, Inc. generates revenue through the development and commercialization of its proprietary drug candidates. The company's key revenue streams include licensing agreements with other pharmaceutical companies, sales of its approved therapies, and potential milestone payments and royalties from its strategic partnerships. These partnerships often involve collaborations for research and development, as well as co-commercialization opportunities, allowing ArriVent to expand its market reach and accelerate product development.

ArriVent BioPharma, Inc. Financial Statement Overview

Summary

ArriVent BioPharma, Inc. is in its growth phase with no revenue and substantial R&D investments. Despite high operating losses, the balance sheet shows strong equity and low leverage. Cash flows indicate a need for external financing to support operations.

Income Statement

ArriVent BioPharma, Inc. showed no revenue or gross profit, with increasing net losses over the years. EBIT and EBITDA margins are negative, reflecting high operating losses, typical for a biotech company in the development phase.

Balance Sheet

The company's balance sheet shows strong equity and low debt levels, with a low debt-to-equity ratio. Stockholders' equity has increased over the years, indicating good financial stability despite operating losses.

Cash Flow

Cash flow analysis reveals negative free cash flow due to high operating expenses, typical for biotech firms focusing on R&D. However, the company has been successful in raising financing, maintaining substantial cash reserves.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00
	EBIT
0.00	-74.59M	-36.91M	-8.70M
	EBITDA
0.00	-74.59M	-36.91M	-51.61M
	Net Income Common Stockholders
-80.49M	-69.33M	-36.91M	-51.61M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
218.86M	150.39M	163.37M	37.28M
	Total Assets
274.94M	163.10M	182.83M	43.04M
	Total Debt
176.00K	317.00K	139.00K	0.00
	Net Debt
-74.12M	-150.07M	-163.23M	-37.28M
	Total Liabilities
17.29M	11.80M	8.37M	1.82M
	Stockholders Equity
257.65M	151.30M	174.46M	41.22M
Cash Flow		Free Cash Flow
-70.21M	-55.84M	-43.63M	-12.59M
	Operating Cash Flow
-70.21M	-55.84M	-43.63M	-12.59M
	Investing Cash Flow
-192.47M	0.00	0.00	-40.00M
	Financing Cash Flow
186.58M	42.86M	169.72M	89.87M

ArriVent BioPharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 16.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVBP, the sentiment is Negative. The current price of 16.42 is below the 20-day moving average (MA) of 19.55, below the 50-day MA of 23.49, and below the 200-day MA of 24.84, indicating a bearish trend. The MACD of -1.62 indicates Positive momentum. The RSI at 29.14 is Positive, neither overbought nor oversold. The STOCH value of 27.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVBP.

ArriVent BioPharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$3.64B	-16.80	-14.99%	6.38%	25.64%	-79.38%
ADAP	46 Neutral	$66.06M	―	-273.36%	―	194.23%	45.50%
FATE	42 Neutral	$86.28M	―	-54.21%	―	-78.55%	-0.92%
AVBP	39 Underperform	$558.55M	―	-39.36%	―	―	-15.71%
ALDX	34 Underperform	$112.85M	―	-58.54%	―	―	-47.28%
ATRA	25 Underperform	$32.75M	―	1063.61%	―	1404.02%	59.49%

ArriVent BioPharma, Inc. Corporate Events

ArriVent BioPharma Expands Oncology Pipeline with New License

On January 21, 2025, ArriVent BioPharma, Inc. entered into an exclusive license agreement with Lepu Biopharma Co., Ltd. to develop and commercialize MRG007, an antibody-drug conjugate for gastrointestinal cancers, outside of Greater China. This agreement entitles Lepu Biopharma to $47 million in upfront and milestone payments and potential additional payments based on development, regulatory, and sales milestones. This strategic move expands ArriVent’s pipeline and strengthens its position in the oncology market by potentially offering a new treatment for gastrointestinal cancers globally.